ClearPoint Neuro

Novo Integrated Sciences (NASDAQ: NVOS) Stock Quote

Last Trade: US$0.13 -0.0026 -1.98
Volume: 2,659,081
5-Day Change: -14.31%
YTD Change: -36.00%
Market Cap: US$18.570M

Latest News From Novo Integrated Sciences

BELLEVUE, Wash. / May 26, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the fiscal quarter ended February 28, 2023. Robert Mattacchione,... Read More
BELLEVUE, Wash. / May 24, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the fiscal quarter ended November 30, 2022. Robert Mattacchione,... Read More
The Company to Receive a Lump Sum of $57,000,000 Note has a non-compounding yield of 1.52% (zero coupon) per annum BELLEVUE, Wash. / Apr 27, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the issuance of an unsecured 15-year $70,000,000 promissory note with RC Consulting LLC in favor of SCP Tourbillion Monaco (the “Buyer”), for a lump sum debt funding of... Read More
BELLEVUE, Wash. / Apr 03, 2023 / Business Wire / Novo Integrated Sciences, Inc. ( NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2022. Robert Mattacchione,... Read More
BELLEVUE, Wash. / Mar 24, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows: As previously reported, on December 23, 2022, Novo entered into a Share Purchase Agreement (the “SWAG Agreement”) with SwagCheck Inc. (“SWAG”) and the shareholders of SWAG, pursuant to which Novo agreed to purchase 100% of... Read More
BELLEVUE, Wash. / Jan 30, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today reported that it received a notice on January 25, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) as a result of its failure... Read More
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows: As previously reported, on December 23, 2022, Novo entered into a Share Purchase Agreement (the “SWAG Agreement”) with SwagCheck Inc. (“SWAG”) and the shareholders of SWAG, pursuant to which Novo agreed to purchase 100% of SWAG’s outstanding shares. SWAG holds a specific... Read More
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today reported that it received a notice (the “Notice) on December 15, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to timely file its... Read More
C4 Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB